Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nano-X To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Nano-X between March 31, 2025 and April 17, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 7, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Nano-X Imaging Ltd.
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Kirby McInerney LLP reminds Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX) investors of the August 11, 2026 deadline to seek the role of lead plaintiff in a pending federal securities class action. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 26-cv-07062, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Nano-X securities between March 31, 2025 and April 17, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between March 31, 2025 and April 17, 2026, inclusive (the “Class Period”), of the important August 11, 2026 lead plaintiff deadline.
If you purchased or acquired Nano-X securities between March 31, 2025 and April 17, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.
LOS ANGELES, July 07, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 11, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) securities between March 31, 2025 and April 17, 2026, inclusive (the “Class Period”).
New York, New York--(Newsfile Corp. - July 7, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Nano-X Imaging Ltd. (NASDAQ: NNOX) and certain of its officers.
LOS ANGELES, July 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nano-X Imaging Ltd. ("Nano-X" or "the Company") (NASDAQ: NNOX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.
LOS ANGELES, July 07, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nano-X Imaging Ltd. (“Nano-X” or “the Company”) (NASDAQ: NNOX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
New SCCT abstracts from Brigham and Women's Hospital highlight the performance and clinical utility of Nanox.AI's FDA-cleared cardiac AI solution, showing high agreement with expert assessment and its potential role in supporting guideline-directed preventive care.
